Recruiting

CPAP vs. HFNC

Sponsor:

The Hospital for Sick Children

Code:

NCT07600333

Conditions

Obstructive Sleep Apnea (OSA)

Eligibility Criteria

Sex: All

Age: 2 - 18

Healthy Volunteers: Not accepted

Interventions

High Flow Nasal Cannula

Continuous Positive Airway Pressure

Study Details

Brief summary:

This study is looking at two different treatments for obstructive sleep apnea (OSA) in children. OSA is a sleep condition where breathing repeatedly stops and starts during sleep, which can affect a child's health, behavior, learning, and quality of life.

Children with moderate-to-severe OSA who cannot be treated with surgery are often prescribed Continuous Positive Airway Pressure (CPAP). CPAP uses a mask worn during sleep to deliver pressurized air and keep the airway open. Although CPAP is effective, many children have difficulty using it regularly because it can feel uncomfortable or hard to tolerate.

This study compares CPAP with another treatment called High-Flow Nasal Cannula (HFNC). HFNC delivers warm, humidified air through soft nasal prongs and may be more comfortable and easier for children to use while still helping keep the airway open during sleep.

Children aged 2 to 18 years with moderate-to-severe OSA will be randomly assigned to use either CPAP or HFNC at home during sleep for 3 months. The study will measure how much each treatment is used, how well it improves sleep-related symptoms and quality of life, how comfortable it is for children, and how it affects caregivers.

The goal of this study is to find out whether HFNC is a comfortable and effective alternative to CPAP for treating obstructive sleep apnea in children.

Conditions

Obstructive Sleep Apnea (OSA)

Study ID

NCT07600333

Start date

May 27, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2031

Anticipated

Primary completion date

Nov, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2 - 18

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Aged 2 to 18 years
  • Diagnosed with moderate to severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index (OAHI) ≥5 events/hour, confirmed by an in-laboratory polysomnography within the previous 6 months
  • Deemed to require Continuous Positive Airway Pressure (CPAP) therapy as part of usual clinical care
  • Ability of the participant and/or parent or legal guardian to provide informed consent (and assent when applicable)

Exclusion Criteria:

  • Predominant or pathological central sleep apnea (central apnea-hypopnea index ≥5 events/hour)
  • Chronic respiratory failure or medical conditions requiring ventilatory support with a set respiratory rate (e.g., neuromuscular disease requiring bilevel ventilation with a backup rate)
  • Hypoventilation requiring non-invasive ventilation with a set respiratory rate
  • History of pneumothorax or pneumomediastinum
  • Uncontrolled gastroesophageal reflux and/or recurrent vomiting
  • Uncontrolled oral secretions
  • Prior use of CPAP or High-Flow Nasal Cannula therapy for treatment of obstructive sleep apnea within the previous 12 months

Study Design

Enrollment

258 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Continuous Positive Airway Pressure (CPAP)

Participants assigned to this arm will receive Continuous Positive Airway Pressure (CPAP) therapy for the treatment of obstructive sleep apnea. CPAP delivers pressurized air through a mask worn during sleep to keep the airway open. Participants will use CPAP at home each night during sleep for a three-month intervention period, with device settings optimized based on standard clinical care.

experimental: High-Flow Nasal Cannula (HFNC)

Participants assigned to this arm will receive High-Flow Nasal Cannula (HFNC) therapy for the treatment of obstructive sleep apnea. HFNC delivers warmed, humidified air at high flow rates through soft nasal prongs to support airway patency during sleep. Participants will use HFNC at home each night during sleep for a three-month intervention period, with flow settings optimized based on standard clinical care.

Interventions

High Flow Nasal Cannula

High-Flow Nasal Cannula (HFNC) therapy delivers warmed, humidified air at high flow rates through soft nasal prongs during sleep to support upper airway patency in children with obstructive sleep apnea. The therapy is used nightly at home, with flow settings optimized according to standard clinical care and overnight sleep study titration.

Continuous Positive Airway Pressure

Continuous Positive Airway Pressure (CPAP) therapy delivers pressurized air through a nasal or oronasal mask worn during sleep to maintain upper airway patency and treat obstructive sleep apnea. CPAP therapy is used nightly at home, with pressure settings optimized according to standard clinical care and overnight sleep study titration.

Primary outcome measure

  • Adherence [ Time Frame: 3 months ]

Central Contacts and Locations

Central contacts

Locations

The Hospital for Sick Children

Recruiting

Toronto, Ontario, Canada

Contacts

Principal Investigator:

Indra Narang

More Information

Sponsor

The Hospital for Sick Children

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • obstructive sleep apnea
  • pediatric obstructive sleep apnea
  • children
  • adolescents
  • continuous positive airway pressure
  • CPAP
  • High Flow nasal cannula
  • HFNC
  • Sleep-disordered breathing
  • adherence
  • quality of life
  • home sleep therapy
  • randomized controlled trial

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by The Hospital for Sick Children on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.